ORKA Oruka Therapeutics, Inc.

NASDAQ
$105.35

Oruka Therapeutics, Inc. (ORKA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Subdued Selling ran below ORKA's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 6 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
4
22 transactions
Purchases
$0
0 shares
Sales
$6.0M
62,000 shares
Net activity
-$6.0M
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $6.0M 22 transactions · 62,000 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $1.4M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
BALL KRISTINE M 6 fills Director Sell 10b5-1 18,000 $104.93 $1.9M 16,804 −51.7% of holding
Agarwal Arjun 6 fills Senior Vice President, Finance Sell 10b5-1 10,000 $104.97 $1.0M 23,719 −29.7% of holding
Klein Lawrence Otto 5 fills Chief Executive Officer Sell 10b5-1 25,000 $95.60 $2.4M 941,662 −2.6% of holding
Quinlan Paul T 5 fills General Counsel Sell 10b5-1 9,000 $78.53 $706.7K 38,595 −18.9% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.